Financial reports
10-Q
2020 Q3
Quarterly report
29 Oct 20
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
8 May 20
10-K
2019 FY
Annual report
26 Feb 20
10-Q
2019 Q3
Quarterly report
31 Oct 19
10-Q
2019 Q2
Quarterly report
1 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
15 Apr 19
NT 10-K
Notice of late annual filing
1 Apr 19
10-Q
2018 Q3
Quarterly report
6 Nov 18
Current reports
8-K
Entry into a Material Definitive Agreement
26 Jan 21
8-K
Submission of Matters to a Vote of Security Holders
20 Jan 21
8-K
Other Events
12 Jan 21
8-K
Eidos Therapeutics Reports Third Quarter 2020 Financial Results and Business Update
29 Oct 20
8-K
Entry into a Material Definitive Agreement
6 Oct 20
8-K
Bridgebio Pharma and Eidos Therapeutics Announce Merger Agreement
5 Oct 20
8-K
Regulation FD Disclosure
29 Sep 20
8-K
Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors
7 Aug 20
8-K
Eidos Therapeutics Reports Second Quarter 2020 Financial Results and Business Update
6 Aug 20
8-K
Departure of Directors or Certain Officers
1 Jun 20
Registration and prospectus
15-12B
Securities registration termination
5 Feb 21
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 21
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 21
POS AM
Prospectus update (post-effective amendment)
26 Jan 21
25-NSE
Exchange delisting
26 Jan 21
425
Business combination disclosure
13 Jan 21
425
Business combination disclosure
13 Jan 21
425
Business combination disclosure
12 Jan 21
425
Business combination disclosure
12 Jan 21
Other
EFFECT
Notice of effectiveness
28 Jan 21
UPLOAD
Letter from SEC
8 Jul 20
CORRESP
Correspondence with SEC
1 Jul 20
UPLOAD
Letter from SEC
22 Jun 20
SEC STAFF
SEC staff action: Order
28 Feb 20
SEC STAFF
SEC staff action: Order
3 Feb 20
EFFECT
Notice of effectiveness
4 Sep 19
CORRESP
Correspondence with SEC
27 Aug 19
CORRESP
Correspondence with SEC
23 Aug 19
UPLOAD
Letter from SEC
13 Aug 19
Ownership